shutterstock_325249841_esb_professional

ESB Professional / Shutterstock.com

29 March 2022Big PharmaAlex Baldwin

ImmunoGen cancer treatment application gets another chance

ImmunoGen has been given the go-ahead to revive its patent application for a cancer treatment dosage following a Federal Circuit ruling on Friday.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Federal Circuit dismisses Phigenix patent appeal in ImmunoGen case

10 January 2017 Pharmaceutical research company Phigenix lost an appeal at the US Court of Appeals for the Federal Circuit yesterday, after the court found that the company lacked standing in a patent case against ImmunoGen.

Takeda signs deal with ImmunoGen to develop cancer drugs

25 March 2015 Massachusetts-based biotechnology company ImmunoGen has granted pharmaceutical company Takeda exclusive rights to use its antibody-drug conjugate technology to develop and commercialise cancer drugs.

More on this story

Federal Circuit dismisses Phigenix patent appeal in ImmunoGen case

10 January 2017 Pharmaceutical research company Phigenix lost an appeal at the US Court of Appeals for the Federal Circuit yesterday, after the court found that the company lacked standing in a patent case against ImmunoGen.

Takeda signs deal with ImmunoGen to develop cancer drugs

25 March 2015 Massachusetts-based biotechnology company ImmunoGen has granted pharmaceutical company Takeda exclusive rights to use its antibody-drug conjugate technology to develop and commercialise cancer drugs.

More on this story

Federal Circuit dismisses Phigenix patent appeal in ImmunoGen case

10 January 2017 Pharmaceutical research company Phigenix lost an appeal at the US Court of Appeals for the Federal Circuit yesterday, after the court found that the company lacked standing in a patent case against ImmunoGen.

Takeda signs deal with ImmunoGen to develop cancer drugs

25 March 2015 Massachusetts-based biotechnology company ImmunoGen has granted pharmaceutical company Takeda exclusive rights to use its antibody-drug conjugate technology to develop and commercialise cancer drugs.

More features

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB